[
  {
    "ts": null,
    "headline": "Bio-Techne Corporation (TECH) Presents at Stephens Annual Investment Conference 2025 Transcript",
    "summary": "Bio-Techne Corporation (TECH) Stephens Annual Investment Conference 2025 November 18, 2025 9:00 AM ESTCompany ParticipantsJames Hippel - Executive VP of...",
    "url": "https://finnhub.io/api/news?id=6e67110e7c151e9d5501fedece2105b7e6f94210972702a36e59ede4bddf91a4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763483931,
      "headline": "Bio-Techne Corporation (TECH) Presents at Stephens Annual Investment Conference 2025 Transcript",
      "id": 137540915,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "TECH",
      "source": "SeekingAlpha",
      "summary": "Bio-Techne Corporation (TECH) Stephens Annual Investment Conference 2025 November 18, 2025 9:00 AM ESTCompany ParticipantsJames Hippel - Executive VP of...",
      "url": "https://finnhub.io/api/news?id=6e67110e7c151e9d5501fedece2105b7e6f94210972702a36e59ede4bddf91a4"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.",
    "url": "https://finnhub.io/api/news?id=2ef22dfc16397d16688ec2c4fb7a072a2f37040755789d0eeca150a63674eeb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763465400,
      "headline": "Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio",
      "id": 137538642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod Bio, a Seattle-based biotechnology company spun out from the Nobel Prize-winning David Baker lab at the University of Washington, Institute for Protein Design. The agreement grants Bio-Techne exclusive commercial rights to a specific subset of Monod's NovoBody™ Duo molecules, a new class of AI-designed bispecific binding proteins.",
      "url": "https://finnhub.io/api/news?id=2ef22dfc16397d16688ec2c4fb7a072a2f37040755789d0eeca150a63674eeb0"
    }
  }
]